Efficacy and safety of visnadine in the treatment of symptoms of sexual dysfunction in heterosexual women: a systematic review of randomized clinical trials

References

• Kingsberg SA, Althof S, Simon JA, et al. Female sexual dysfunction-medical and psychological treatments, committee 14. J Sex Med. 2017;14(12):1–10. doi: 10.1016/j.jsxm.2017.05.018.
   PubMed Web of Science ®Google Scholar
• Weinberger JM, Houman J, Caron AT, et al. Female sexual dysfunction: a systematic review of outcomes across various treatment modalities. Sex Med Rev. 2019;7(2):223–250. doi: 10.1016/j.sxmr.2017.12.004.
   PubMed Web of Science ®Google Scholar
• Salonia A, Giraldi A, Chivers ML, et al. Physiology of women’s sexual function: basic knowledge and new findings. J Sex Med. 2010;7(8):2637–2660. doi: 10.1111/j.1743-6109.2010.01810.x.
   PubMed Web of Science ®Google Scholar
• Nappi RE, Cucinella L, Martella S, et al. Female sexual dysfunction (FSD): prevalence and impact on quality of life (QoL). Maturitas. 2016;94:87–91. doi: 10.1016/j.maturitas.2016.09.013.
   PubMed Web of Science ®Google Scholar
• McCabe MP, Sharlip ID, Lewis R, et al. Incidence and prevalence of sexual dysfunction in women and men: a consensus statement from the fourth international consultation on sexual medicine 2015. J Sex Med. 2016;13(2):144–152. doi: 10.1016/j.jsxm.2015.12.034.
   PubMed Web of Science ®Google Scholar
• Molkara T, Motavasselian M, Akhlaghi F, et al. The effects of herbal medicines on women sexual dysfunction: a systematic review. Curr Drug Discov Technol. 2021;18(6):e130921186972–16. doi: 10.2174/1570163817666201019130139.
   PubMedGoogle Scholar
• Stein A, Sauder SK, Reale J. The role of physical therapy in sexual health in men and women: evaluation and treatment. Sex Med Rev. 2019;7(1):46–56. doi: 10.1016/j.sxmr.2018.09.003.
   PubMed Web of Science ®Google Scholar
• Jurado AR, Jouda-Benazouz M, Mendoza-Huertas L, et al. The use of natural products for the treatment of female sexual dysfunction: a systematic review of randomized clinical trials. ASM. 2020;10(02):56–69. doi: 10.4236/asm.2020.102004.
   Google Scholar
• Santos Silva IM, Paula Pinto M, Gonçalves D. Educational programs and sexual counselling for postmenopausal sexual dysfunction: a systematic review and meta-analysis. J Sex Med. 2022;19(1):54–63. doi: 10.1016/j.jsxm.2021.09.017.
   PubMed Web of Science ®Google Scholar
• Caruso S, Di Pasqua S. Update on pharmacological management of female sexual dysfunctions. Sexologies. 2019;28(2):e1–e5. doi: 10.1016/j.sexol.2019.02.002.
   Google Scholar
• Weinberger JM, Houman J, Caron AT, et al. Female sexual dysfunction and the placebo effect. Obstet Gynecol. 2018;132(2):453–458. doi: 10.1097/AOG.0000000000002733.
   PubMed Web of Science ®Google Scholar
• Khalil N, Bishr M, Desouky S, et al. Ammi visnaga L., a potential ­medicinal plant: a review. Molecules. 2020;25(2):301. doi: 10.3390/molecules25020301.
   PubMed Web of Science ®Google Scholar
• Ahmed S, Fahim J, Abdelmohsen U. Chemical and biological potential of ammi visnaga (L.) lam. and apium graveolens L.: a review (1963-2020). J Adv Biomed Pharma Sci. 2021;4(3):160–176.
   Google Scholar
• Rauwald H, Brehm O, Odenthal KP. The involvement of a Ca 2+ channel blocking mode of action in the pharmacology of ammi visnaga fruits 1. Planta Med. 1994;60(2):101–105. doi: 10.1055/s-2006-959426.
   PubMed Web of Science ®Google Scholar
• Venugopala KN, Rashmi V, Odhav B. Review on natural coumarin lead compounds for their pharmacological activity. Biomed Res Int. 2013;2013:963248–963214. doi: 10.1155/2013/963248.
   PubMed Web of Science ®Google Scholar
• Duarte J, Pérez-Vizcaíno F, Torres AI, et al. Vasodilator effects of visnagin in isolated rat vascular smooth muscle. Eur J Pharmacol. 1995;286(2):115–122. doi: 10.1016/0014-2999(95)00418-k.
   PubMed Web of Science ®Google Scholar
• Bernorio R, Piloni S, Mori G, et al. Efficacy and tolerability of a spray formulation containing visnadine in women self-reporting sexual symptoms: a randomized double-blind placebo-controlled pilot study. J Endocrinol Invest. 2018;41(6):729–737. doi: 10.1007/s40618-017-0801-0.
   PubMed Web of Science ®Google Scholar
• Caputo A, Natoli A, Radice R, et al. Efficacy of an intimate oil solution containing visnadine in women self-reporting sexual symptoms. Minerva Gynecol. 2018;70(4):490–492.
   PubMedGoogle Scholar
• Caruso S, Mauro D, Cariola M, et al. Randomized crossover study investigating daily versus on-demand vulvar visnadine spray in women affected by female sexual arousal disorder. Gynecol Endocrinol. 2018;34(2):110–114. doi: 10.1080/09513590.2017.1354366.
   PubMed Web of Science ®Google Scholar
• Sparavigna A, Caputo A, Natoli A, et al. A randomized single-blind placebo-controlled study of a visnadine emulgel formulation on healthy postmenopausal women. Minerva Ginecol. 2019;71(5):353–358. doi: 10.23736/S0026-4784.19.04398-3.
   PubMed Web of Science ®Google Scholar
• Laganà AS, Basile F, Stojanovska L, et al. Effects of a new vaginal cream containing visnadine, prenylflavonoids and bovine colostrum on vaginal health index score and female sexual function index in post-menopausal sexually active women affected by vaginal dryness: a pilot study. Maturitas. 2017;100:123. doi: 10.1016/j.maturitas.2017.03.265.
   Google Scholar
• Laganà AS, Vitale SG, Stojanovska L, et al. Preliminary results of a single-arm pilot study to assess the safety and efficacy of visnadine, prenylflavonoids and bovine colostrum in postmenopausal sexually ­active women affected by vulvovaginal atrophy. Maturitas. 2018;109:78–80. doi: 10.1016/j.maturitas.2017.12.015.
   PubMed Web of Science ®Google Scholar
• Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71. Published online March doi: 10.1136/bmj.n71.
   PubMed Web of Science ®Google Scholar
• Rosen R, Brown C, Heiman J, et al. The female sexual function index (FSFI): a multidimensional self-report instrument for the assessment of female sexual function. J Sex Marital Ther. 2000;26(2):191–208.
   PubMed Web of Science ®Google Scholar
• Wiegel M, Meston C, Rosen R. The female sexual function index (FSFI): cross-validation and development of clinical cutoff scores. J Sex Marital Ther. 2005;31(1):1–20. doi: 10.1080/00926230590475206.
   PubMed Web of Science ®Google Scholar
• Isidori AM, Pozza C, Esposito K, et al. Development and validation of a 6-item version of the female sexual function index (FSFI) as a diagnostic tool for female sexual dysfunction. J Sex Med. 2010;7(3):1139–1146. doi: 10.1111/j.1743-6109.2009.01635.x.
   PubMed Web of Science ®Google Scholar
• Chedraui P, Pérez-López FR, Sánchez H, et al. Assessment of sexual function of mid-aged ecuadorian women with the 6-item female sexual function index. Maturitas. 2012;71(4):407–412. doi: 10.1016/j.maturitas.2012.01.013.
   PubMed Web of Science ®Google Scholar
• Pérez-López FR, Fernández-Alonso AM, Trabalón-Pastor M, MenopAuse RIsk Assessment (MARIA) Research Group., et al. Assessment of sexual function and related factors in mid-aged sexually active spanish women with the six-item female sex function index. Menopause. 2012;19(11):1224–1230. doi: 10.1097/gme.0b013e3182546242.
   PubMed Web of Science ®Google Scholar
• Cumpston M, Li T, Page MJ, et al. Updated guidance for trusted systematic reviews: a new edition of the cochrane handbook for systematic reviews of interventions. Cochrane Database Syst Rev. 2019;10(10):ED000142.
   PubMedGoogle Scholar
• Chaikittisilpa S, Orprayoon N. Effects of visnadine, ethyl ximeninate, Coleus Barbatus and Millet in Emulgel on Sexual Function in Postmenopausal Women (NCT04579991). Available athttps://classic.clinicaltrials.gov/ct2/show/NCT04579991?term=NCT04579991&draw=2&rank=1.
   Google Scholar
• Caputo A, Sparavigna A, Natoli A, et al. An open trial of a visnadine emulgel topical application in postmenopausal superficial dyspareunia: daily vs. on-demand use. Minerva Ginecol. 2020;72(1):59–60. doi: 10.23736/S0026-4784.19.04402-2.
   PubMed Web of Science ®Google Scholar
• Campos-Toimil M, Orallo F, Santana L, et al. Synthesis and vasorelaxant activity of new coumarin and furocoumarin derivatives. Bioorg Med Chem Lett. 2002;12(5):783–786. doi: 10.1016/s0960-894x(02)00015-x.
   PubMed Web of Science ®Google Scholar
• Duarte J, Lugnier C, Torres AI, et al. Effects of visnagin on cyclic ­nucleotide phosphodiesterases and their role in its inhibitory effects on vascular smooth muscle contraction. Gen Pharmacol. 1999;32(1):71–74. doi: 10.1016/s0306-3623(98)00083-4.
   PubMedGoogle Scholar
• Aquino J, Parente J, Moreira J, et al. PNM-12 double-blind randomized study on the effect of Non-Hormonal gel application to the genital area of women in the menacme with sexual dysfunction. J Sex Med. 2017;14(Supplement_6):e386–e386. doi: 10.1016/j.jsxm.2017.10.059.
   Google Scholar
• Nappi RE. Why are there no FDA-approved treatments for female sexual dysfunction? Expert Opin Pharmacother. 2015;16(12):1735–1738. doi: 10.1517/14656566.2015.1064393.
   PubMed Web of Science ®Google Scholar
• Miara MD, Bendif H, Rebbas K, et al. Medicinal plants and their traditional uses in the highland region of Bordj Bou Arreridj (northeast Algeria). J Herbal Med. 2019;16:100262. doi: 10.1016/j.hermed.2019.100262.
   Web of Science ®Google Scholar